MedImmune, 3055 Patrick Henry Drive, Santa Clara, CA 95054, USA.
Vaccine. 2010 Feb 3;28(5):1285-93. doi: 10.1016/j.vaccine.2009.11.023. Epub 2009 Nov 25.
An Madin-Darby canine kidney (MDCK) cell line, 9B9-1E4, was cloned by limit dilution from a heterologous cell population and chosen as a potential production cell substrate for cell culture-based influenza vaccine manufacture. Since MDCK cells are transformed cells of canine origin, extensive characterization, including evaluation of tumorigenicity and oncogenicity, was performed to ensure the safety of this cell line for vaccine production. Injection of intact MDCK cells into adult and newborn athymic nude mice did not lead to progressive tumor formation in two separate tumorigenicity studies. In addition, neither MDCK cell lysate nor cellular DNA induced tumors in newborn rodents (athymic nude mice, hamsters and rats) in six oncogenicity studies. Observations from these studies demonstrate the low tumorigenic and oncogenic potential of the MDCK cell clone 9B9-1E4. These observations coupled with other characterization study results strongly suggest a high safety assurance level can be achieved through cell cloning and selection of low tumorigenic and oncogenic cells for influenza vaccine production.
一株 Madin-Darby 犬肾 (MDCK) 细胞系 9B9-1E4 是通过有限稀释从异源细胞群中克隆出来的,被选为细胞培养流感疫苗生产的潜在生产细胞基质。由于 MDCK 细胞是犬源性的转化细胞,因此进行了广泛的特征描述,包括评估致瘤性和致癌性,以确保该细胞系用于疫苗生产的安全性。将完整的 MDCK 细胞注射到成年和新生无胸腺裸鼠中,在两项独立的致瘤性研究中均未导致进行性肿瘤形成。此外,在六项致癌性研究中,MDCK 细胞裂解物或细胞 DNA 均未在新生啮齿动物(无胸腺裸鼠、仓鼠和大鼠)中诱导肿瘤。这些研究的观察结果表明 MDCK 细胞克隆 9B9-1E4 的致瘤性和致癌性潜力较低。这些观察结果以及其他特征描述研究结果强烈表明,通过细胞克隆和选择低致瘤性和致癌性细胞,可以实现流感疫苗生产的高安全性保证水平。